Europe's Drug Regulator To Make Finding On Johnson & Johnson Vaccine Next Week
The Amsterdam-based European Medicines Agency's announcement also comes as the US pharmaceutical company itself said it was delaying rollout of its vaccine on the continent.
Europe's medicines regulator said Wednesday it will make a recommendation on the safety of Johnson & Johnson's coronavirus jab next week after US health authorities recommended pausing vaccinations over blood clot fears.
The Amsterdam-based European Medicines Agency's announcement also comes as the US pharmaceutical company itself said it was delaying rollout of its vaccine on the continent.
The "EMA is expediting this evaluation and currently expects to issue a recommendation next week," it said in a statement, after announcing last week a probe had been launched.
"While its review is ongoing, EMA remains of the view that the benefits of the vaccine in preventing Covid-19 outweigh the risks of side effects," the medicines watchdog added.
The US Food and Drug Administration and the Centers for Disease Control on Tuesday recommended a "pause" on the one-jab Covid-19 vaccine on worries over six reported cases of a rare type of blood clot in the United States.
Johnson & Johnson then said it "made the decision to proactively delay the rollout of our vaccine in Europe," adding that it was reviewing the cases with European health authorities.
Question marks now hover over the adenovirus-type vaccines produced by AstraZeneca and Johnson & Johnson after several blood clot cases in people who have received the shots.
While the EMA has authorised AstraZeneca for all adults, many EU countries have taken the precaution of limiting its use to only older segments of the population.
The EMA added that its probe into the "very rare" forming of blood clots from AstraZeneca's vaccine continued.
"The review by EMA's human medicines committee (CHMP) will enable authorities to put the risks of Vaxzevria into the context of the benefits of ongoing vaccination campaigns," the agency said, referring to AstraZeneca's vaccine.
The Amsterdam-based European Medicines Agency's announcement also comes as the US pharmaceutical company itself said it was delaying rollout of its vaccine on the continent.
The "EMA is expediting this evaluation and currently expects to issue a recommendation next week," it said in a statement, after announcing last week a probe had been launched.
"While its review is ongoing, EMA remains of the view that the benefits of the vaccine in preventing Covid-19 outweigh the risks of side effects," the medicines watchdog added.
The US Food and Drug Administration and the Centers for Disease Control on Tuesday recommended a "pause" on the one-jab Covid-19 vaccine on worries over six reported cases of a rare type of blood clot in the United States.
Johnson & Johnson then said it "made the decision to proactively delay the rollout of our vaccine in Europe," adding that it was reviewing the cases with European health authorities.
Question marks now hover over the adenovirus-type vaccines produced by AstraZeneca and Johnson & Johnson after several blood clot cases in people who have received the shots.
While the EMA has authorised AstraZeneca for all adults, many EU countries have taken the precaution of limiting its use to only older segments of the population.
The EMA added that its probe into the "very rare" forming of blood clots from AstraZeneca's vaccine continued.
"The review by EMA's human medicines committee (CHMP) will enable authorities to put the risks of Vaxzevria into the context of the benefits of ongoing vaccination campaigns," the agency said, referring to AstraZeneca's vaccine.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
